期刊文献+

2023年慢性阻塞性肺疾病全球倡议更新评述

Review of updates 2023 global initiative for chronic obstructive pulmonary disease
下载PDF
导出
摘要 慢性阻塞性肺病(COPD)发病机制复杂,是一种复杂累积和动态的基因-环境-时间相互作用的最终结果,这些相互作用会损害肺部和/或改变其正常的发育。COPD目前是全球范围内发病率和死亡率的主要原因,其经济和社会负担正在不断增加。本文根据2023年慢性阻塞性肺疾病全球倡议(GOLD)的更新,就COPD定义、诊断和治疗等关键问题进行评述,以期为临床医师诊断和治疗COPD患者提供参考和借鉴。 Chronic obstructive pulmonary disease(COPD),a chronic disease with complicated pathogenesis,is the end-result of complex,cumulative and dynamic Gene-Environment-Time interactions over the lifetime that can damage the lung and/or alter normal development.COPD is a leading cause of morbidity and mortality worldwide,accounting for heavy economic and social burden which are continuously increasing.In order to provide clinical references for its diagnosis and treatment,this article reviewed the key issues of COPD,including definition,diagnosis,and therapy,which are based on the update of 2023 Global Initiative for Chronic Obstructive Lung Disease(GOLD).
作者 吴晓娟 杜发旺 罗晓斌 李丽 王小川 王勤 熊伟 朱涛 WU Xiaojuan;DU Fawang;LUO Xiaobin;LI Li;WANG Xiaochuan;WANG Qin;XIONG Wei;ZHU Tao(Department of Respiratory and Critical Care Medicine,Suining Central Hospital,Suining 629000,Sichuan,China;Department of Respiratory and Critical Care Medicine,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)
出处 《西部医学》 2024年第1期1-5,共5页 Medical Journal of West China
基金 国家自然科学基金青年项目(8180011074) 四川省自然科学基金(面上项目)(23NSFSC0667) 四川省卫生健康委员会科技项目(临床研究专项)(23LCYJ008) 中华国际医学交流基金会呼吸疾病青年实用研究项目(Z-2017-24-2301)。
关键词 慢性阻塞性肺疾病 GOLD 气流阻塞 药物治疗 病情评估 Chronic obstructive pulmonary disease Global initiative for chronic obstructive lung disease Airway obstruction Drug treatment Disease assessment
  • 相关文献

参考文献2

二级参考文献28

  • 1Frith PA, Thompson PJ, Ratnavadivel R,et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial f-J]. Thorax,2015,70(6) :519-527.
  • 2Liu Y, Shi H, Sun X,et al. Benefits of adding flutieasone propi- onate/salmeterol to tiotropium in COPD: a meta~analysis I-J-1. Eur J Intern Med,2014,25(5):491-495.
  • 3Ismaila A, Corriveau D, Vaillancourt J,et al. Impact of adher- ence to treatment with tiotropium and fluticasone propionate/ salmeterol in chronic obstructive pulmonary diseases patients EJ]. Curr Med Res Opin,2014,30(7) :1427-1436.
  • 4Maltais F, Mahler DA, Pepin V,et al. Effect of fluticasone pro- pionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD [J']. Eur Respir J, 2013,42 (2) ~ 5a9-541.
  • 5Hoshino M, Ohtawa J. Effects of tiotropium and salmeterol/flu- tieasone propionate on airway wall thickness in chronic obstruc- tive pulmonary disease [J]. Respiration, 2013,86 (4) : 280-287.
  • 6Szmidt M. The influence of treatment with formoterol, formot- erol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and sim- ple, morning everyday activities in patients with chronic ob- structive pulmonary disease (COPD)[J]. Pneumonol Alergol Pol,2012,80(3) :255-262.
  • 7Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary dis- ease I-J]. Drugs,2012,72(2) :273-300.
  • 8Cheng T, Wan H, Cheng Q,et al. Computed tomography manifesta- tion of acute exacerbation of chronic obstructive pulmonary disease: A pilot study EJ3. Exp Ther Med,2016,11(2) :519-529.
  • 9Hajizadeh N, Goldfeld K. Burden of Transitions After Invasive Mechanical Ventilation for U. S. Individuals with Severe Chronic Obstructive Pulmonary Disease. Opportunity to Prepare for Preference-Congruent End-of-Life Care [J~. J Am Geriatr Soc, 2016,64(2) :434-435.
  • 10Wang T, Mao Y, Sun Y, et al. Pulmonary hypertension in pa- tients with chronic obstructive pulmonary disease: clinical char- acteristics and risk factors EJ3. Zhonghua Nei Ke Za Zhi, 2015, 54(12) : 1037-1040.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部